Participated · Series B · Apr 2026

Beacon Biosignals develops FDA-cleared wearable EEG technology combined with advanced AI to capture and analyze real-world neural data. Its platform provides clinicians and biopharma partners with objective measures of brain function intended to accelerate research, improve diagnostics and guide new treatments across neurology, psychiatry and sleep medicine. The company is led by CEO Jacob Donoghue and is based in Boston, MA. Beacon reported cumulative funding of over $132M following the Series B extension. The company plans to use the new proceeds to further scale at-home EEG deployments and expand its analytics capabilities to support diagnostics, clinical trials and precision medicine.

Led · Series C · Oct 2020

InCarda Therapeutics is a privately-held, clinical-stage biopharmaceutical company developing first-of-their-kind inhaled therapies for acute cardiovascular diseases. Its lead product, InRhythm (flecainide for inhalation), is designed to rapidly deliver flecainide to the heart via the lungs to restore normal sinus rhythm in patients with recent-onset paroxysmal atrial fibrillation (PAF). InCarda completed the open-label, dose-escalation Part A of the INSTANT Phase 2 trial, will present Phase 2 data at the American Heart Association Scientific Sessions 2020, and has commenced enrollment of a confirmatory cohort and a patient-led substudy. The company is finalizing plans for a multinational pivotal Phase 3 trial in a medically supervised setting expected to initiate in H1 2021 and ultimately aims to develop a portable, patient self-administered version for use outside medical settings. InCarda employs a de-risked approach by reformulating approved drugs for inhalation to achieve rapid onset, lower off-target exposure, and smaller effective doses. The company announced a $30 million first close of a Series C equity financing to fund ongoing clinical development of InRhythm. InCarda is developing first-of-their-kind inhaled therapies for acute cardiovascular diseases, leveraging pulmonary delivery to rapidly target cardiac tissue. Its lead program, InRhythm (flecainide for inhalation), is designed to deliver flecainide via the lungs to rapidly convert patients with paroxysmal atrial fibrillation (PAF) back to normal sinus rhythm and relieve symptoms. Phase 1 results demonstrated rapid and safe delivery with ECG changes consistent with potential to restore normal sinus rhythm, and the company has initiated a multinational Phase 2 randomized in-hospital study of single and repeat doses. Key study endpoints include percentage of patients converting to NSR within 45 minutes, time to NSR conversion, and time to reduction of AF symptoms; top-line Phase 2 results were anticipated in the second half of 2019. InCarda employs a de‑risked approach by repurposing approved drugs in a new inhaled dosing paradigm to enable rapid onset, lower off-target exposure, and patient self-administration. The company reported an oversubscribed Series B financing to provide runway to advance the InRhythm program and strengthen capital resources and leadership. InCarda Therapeutics is a San Francisco–based biotechnology company developing inhaled therapies to treat acute cardiovascular conditions. Its lead program is an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF). The company is also pursuing additional research concepts that leverage the same inhalation platform to target the heart for other acute cardiac conditions. Led by CEO Grace E. Colon, Ph.D., InCarda intends to use proceeds from its recent Series A to advance the lead PAF program. The company raised over $5M in the Series A financing; the article notes potential additional tranches could bring the total to $1.5M. Management includes a board seat to be filled by Reenie McCarthy of Morningside Venture as part of the financing.